[
  {
    "ts": null,
    "headline": "Biogen (BIIB): Reevaluating Valuation Following FDA’s Supplemental Spinraza Dose Setback",
    "summary": "If you are following Biogen (BIIB), the latest twist from the FDA might have you reevaluating what is next for the stock. On Tuesday, Biogen announced that the agency declined to approve its supplemental application for a higher dose of Spinraza, its treatment for spinal muscular atrophy. The FDA asked for updated technical information in the Chemistry Manufacturing and Controls documentation but made it clear that no concerns exist regarding the supporting clinical evidence. Biogen says it...",
    "url": "https://finnhub.io/api/news?id=11c069729de12d6012478db555a2a006c824375305166bd16132cb29e2fc07f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758980036,
      "headline": "Biogen (BIIB): Reevaluating Valuation Following FDA’s Supplemental Spinraza Dose Setback",
      "id": 136904313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "If you are following Biogen (BIIB), the latest twist from the FDA might have you reevaluating what is next for the stock. On Tuesday, Biogen announced that the agency declined to approve its supplemental application for a higher dose of Spinraza, its treatment for spinal muscular atrophy. The FDA asked for updated technical information in the Chemistry Manufacturing and Controls documentation but made it clear that no concerns exist regarding the supporting clinical evidence. Biogen says it...",
      "url": "https://finnhub.io/api/news?id=11c069729de12d6012478db555a2a006c824375305166bd16132cb29e2fc07f3"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued",
    "summary": "Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics for an initial cash payment of $85 million and milestone payments. The acquisition focuses on the ThecaFlex DRx, an implantable subcutaneous port and catheter device […]",
    "url": "https://finnhub.io/api/news?id=bec44669c5ec51f572c17a30c1c13045d75dd62d24cb8ef4572c28f16af9829b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758949151,
      "headline": "Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued",
      "id": 136904314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics for an initial cash payment of $85 million and milestone payments. The acquisition focuses on the ThecaFlex DRx, an implantable subcutaneous port and catheter device […]",
      "url": "https://finnhub.io/api/news?id=bec44669c5ec51f572c17a30c1c13045d75dd62d24cb8ef4572c28f16af9829b"
    }
  }
]